Benign separation process being advanced for pharmaceutical industry

March 16, 2005

Blacksburg, Va. -- Pharmaceutical companies perform many separations of molecules before they begin to synthesize the most ideal safe, pure, effective compound or sub-compound into a drug.

Despite the concern for safe processes, one of the most chemically benign separation processes has not been available to the drug industry.

Now Virginia Tech researchers with support from Procter & Gamble Pharmaceuticals have made a discovery that may allow a green-chemistry technique known as supercritical fluid chromatography (SFC) to be used in drug development.

The research will be presented at the 229th American Chemical Society national meeting in San Diego on March 13-17.

Drugs must be water-soluble in order to be useful in the body, meaning they are polar, or have some degree of charge. SFC uses carbon dioxide-based fluids for the isolation of compounds. Carbon dioxide is not polar, so could not be used to separate polar drugs, or ionic analytes.

"We discovered you can add a small amount of polar solvent that contains an ionic component that will allow carbon dioxide to separate ionic analytes," said Virginia Tech chemistry professor Larry Taylor. "It opens up an area of drug development to the use of nonpolluting carbon dioxide."

Jun (Sally) Zheng of Wuhan, China, a graduate student in chemistry at Virginia Tech, Taylor, and J. David Pinkston of Procter & Gamble Pharmaceuticals Health Care Research Center in Mason, Ohio, will present the poster, "Supercritical fluid chromatography of ionic analytes (MEDI 569)," from 6 to 8 p.m. Wednesday, March 16, as part of the Division of Medicinal Chemistry presentations.

Taylor and other students have been working with Pinkston for three years. Zheng recently joined the team and is studying how the additive allows the experiment to be successful. The company is providing her with a fellowship for spring and summer 2005.
For more information, contact Larry Taylor at (540) 231-6680 or

Poster abstract:
Addition of a small amount of polar solvent (e.g. modifier) which contains an ionic component (e.g. additive) to a CO mobile phase has shown major improvement in the elution of ionic analytes via packed column SFC. The study initially focused on the elution of sodium dodecylbenzene sulfonate. The additives studied were alkylammonium acetates. Conventional and Deltabond cyanopropyl and bare silica were the stationary phases. The effect of additive type and concentration on retention were investigated. Sodium 4- octylbenzenesulfonate and sodium p-toluenesulfonate also were studied. The study then turned to the use of sodium alkylsulfonates as mobile phase additives to elute ammonium salts. Propranolol hydrochloride and benzyltrimethylammonium- and cetylpyridinium-chloride were successfully eluted from the Deltabond phase after five minutes with a sulfonate additive. To gain insight into the elution mechanism(s), solid state NMR of the silica stationary phase has been performed. Modification of the stationary phase and ion pairing with the analyte are two possible elution mechanisms being considered.

Virginia Tech

Related Drug Development Articles from Brightsurf:

FDA support for oncology drug development during COVID-19
This Viewpoint from the U.S. Food and Drug Administration puts into context recent guidance on clinical trials during COVID-19 for oncology and shares insight regarding regulatory challenges and lessons learned.

COVID-19 drug development could benefit from approach used against flu
A new study from researchers at The University of Texas at Austin has found that some antivirals are useful for more than helping sick people get better -- they also can prevent thousands of deaths and hundreds of thousands of virus cases if used in the early stages of infection.

Chemistry breakthrough could speed up drug development
Scientists have successfully developed a new technique to reliably grow crystals of organic soluble molecules from nanoscale droplets, unlocking the potential of accelerated new drug development.

New model of the GI tract could speed drug development
MIT engineers have devised a way to speed new drug development by rapidly testing how well they are absorbed in the small intestine.

Super-charging drug development for COVID-19
Researchers are using cell-free manufacturing to ramp up production of valinomycin, a promising drug that has proven effective in obliterating SARS-CoV in cellular cultures.

Drug development for rare diseases affecting children is increasing
The number of treatments for rare diseases affecting children has increased, a new study suggests.

New opportunity for cancer drug development
After years of research on cell surface receptors called Frizzleds, researchers at Karolinska Institutet in Sweden provide the proof-of-principle that these receptors are druggable by small molecules.

Novel paradigm in drug development
Targeted protein degradation (TPD) is a new paradigm in drug discovery that could lead to the development of new medicines to treat diseases such as cancer more effectively.

Turbo chip for drug development
In spite of increasing demand, the number of newly developed drugs decreased continuously in the past decades.

A breakthrough for brain tumor drug development
Glioblastoma is a devastating disease with poor survival stats due in part to a lack of preclinical models for new drug testing.

Read More: Drug Development News and Drug Development Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to